Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Return on Capital Employed (2021 - 2023)

Historic Return on Capital Employed for Immuneering (IMRX) over the last 3 years, with Q4 2023 value amounting to 0.58%.

  • Immuneering's Return on Capital Employed fell 1500.0% to 0.58% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.58%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.56% for FY2023, which is 1800.0% down from last year.
  • According to the latest figures from Q4 2023, Immuneering's Return on Capital Employed is 0.58%, which was down 1500.0% from 0.49% recorded in Q3 2023.
  • Over the past 5 years, Immuneering's Return on Capital Employed peaked at 0.21% during Q4 2021, and registered a low of 0.58% during Q4 2023.
  • Over the past 3 years, Immuneering's median Return on Capital Employed value was 0.4% (recorded in 2022), while the average stood at 0.39%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -1000bps in 2022, then tumbled by -2300bps in 2023.
  • Over the past 3 years, Immuneering's Return on Capital Employed (Quarter) stood at 0.21% in 2021, then tumbled by -103bps to 0.43% in 2022, then crashed by -35bps to 0.58% in 2023.
  • Its Return on Capital Employed was 0.58% in Q4 2023, compared to 0.49% in Q3 2023 and 0.5% in Q2 2023.